医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Presbia Introduces Time-Saving Disposable Microlens Inserter

2015年10月05日 PM09:00
このエントリーをはてなブックマークに追加


 

DUBLIN

Presbia PLC (NASDAQ: LENS), an ophthalmic device company introduced its new, innovative disposable inserter for the Presbia Flexivue Microlens™ at the Australasian Society of Cataract and Refractive Surgeons (AUSCRS) conference held from October 7th through the 10th in Noosa, Queensland, Australia. The Presbia Flexivue Microlens is a proprietary optical lens implant for treating presbyopia, the age-related loss of near-vision. With its simplified action, the new inserter further reduces the time required to complete the Presbia Flexivue Microlens procedure, allowing surgeons to safely complete more procedures per hour of surgery time.

The disposable inserter meets the requests of many surgeons and their staffs to have single-use instruments in their clinics to minimize the risk of patient infection. The disposable inserter compliments Presbia’s reusable inserter, widely-used today, offering surgeons an option to select the instrument that best suits their needs.

“Our goal is to provide surgeons with the best surgical solution to address the loss of near-vision, while providing the most efficient and safest tools for lens insertion,” said Todd Cooper, President and CEO of Presbia. “We are pleased to be making this announcement at AUSCRS as Australia, New Zealand, and South Korea are integral parts of our commercialization expansion strategy.”

Forward-Looking Statements

Information provided and statements contained in this press release that are not purely historical are forward-looking statements. Such forward-looking statements only speak as of the date of this press release and Presbia assumes no obligation to update the information included in this press release. Statements made in this press release that are forward-looking in nature may involve risks and uncertainties. Accordingly, readers are cautioned that any such forward-looking statements are not guarantees and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Although Presbia believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Unless otherwise required by law, Presbia also disclaims any obligation to update its view of any such risks or uncertainties or to announce publicly the result of any revisions to the forward-looking statements made in this press release.

About Presbia

Presbia PLC (NASDAQ:LENS) is an ophthalmic device company that has developed and is currently marketing the presbyopia-correcting Presbia Flexivue Microlens™, a miniature lens that is implanted in a corneal pocket created by a femtosecond laser. The Presbia Flexivue Microlens™ has received a CE mark for the European Economic Area, allowing the lens to be marketed in over 30 countries across Europe. A staged pivotal U.S. clinical trial for the Presbia Flexivue Microlens™ commenced in 2014.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151005005046/en/

CONTACT

Presbia PLC
Monica Yamada, 323-860-4903
monica@presbia.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma
  • Herbalife Nutrition Hong Kong and Po Leung Kuk Set New World Record in Launching Healthy Active Lifestyle Mobile App
  • Median Technologies Inks a Research Collaboration Agreement for Lung Cancer Screening Programs With Xingtai People’s Hospital, Xingtai City, China
  • Genentech’s HEMLIBRA (emicizumab-kxwh) Every Four Weeks Controlled Bleeds in Phase III Study in Hemophilia A
  • Orthocell Commences Treatment of Its 1,000th Patient